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Abstract 
Background: Malaria rapid diagnostic tests have become a primary and critical tool for malaria diagnosis in malaria-
endemic countries where Plasmodium falciparum Histidine Rich Protein 2-based rapid diagnostic tests (PfHRP2-based 
RDTs) are widely used. However, in the last decade, the accuracy of PfHRP2-based RDTs has been challenged by the 
emergence of P. falciparum strains harbouring deletions of the P. falciparum histidine rich protein 2 (pfhrp2) gene, result-
ing in false-negative results. In the Democratic Republic of Congo (D.R. Congo), little is known about the prevalence 
of the pfhrp2 gene deletion among P. falciparum isolates infecting symptomatic patients, especially in low to moder-
ate transmission areas where pfhrp2 deletion parasites are assumed to emerge and spread. Here we determine the 
local prevalence and factors associated with pfhrp2 gene deletions among symptomatic malaria patients in the Kwilu 
Province of the D.R. Congo.
Methods: We used secondary data from a prospective health facility-based cross-sectional study conducted in 2018. 
Blood was collected for microscopy, PfHRP2-RDT, and spotted onto Whatman filter paper for downstream genetic 
analysis. Genomic DNA was extracted and used to perform PCR assays for the detection and confirmation of pfhrp2 
gene deletions. Fischer’s exact and the Kruskal–Wallis tests were applied to look for associations between potential 
explanatory variables and the pfhrp2 gene deletion with a level of statistical significance set at P < 0.05.
Results: Of the 684 enrolled symptomatic patients, 391 (57.7%) were female. The majority (87.7%) reported the 
presence of mosquito breeding sites within the household’s compound, and fever was the most reported symptom 
(81.6%). The overall prevalence of the pfhrp2 gene deletion was 9.2% (95% CI: 6.7%–12.1%). The deletion of the pfhrp2 
gene was associated with health zone of origin (P = 0.012) and age (P = 0.019). Among false-negative PfHRP2-RDT 
results, only 9.9% were due to pfhrp2 gene deletion.
Conclusions: P. falciparum isolates with pfhrp2 gene deletions are relatively common among symptomatic patients 
in Kwilu province. Further investigations are needed to provide enough evidence for policy change. Meanwhile, the 
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Background
Malaria remains a global health issue despite progress 
over the last decade. In 2018, there were an estimated 228 
million new malaria cases, including 405 000 deaths [1]. 
Ninety-two percent of malaria cases and 93% of malaria 
deaths occurred in Africa. Fifteen countries in sub-Saha-
ran Africa and India carried nearly 80% of the global 
malaria burden of which Nigeria and the Democratic 
Republic of the Congo (D.R. Congo) accounted for about 
35% [1].
D.R. Congo accounts for 12% of all malaria cases in 
sub-Saharan Africa [1]. In D.R. Congo, malaria is the 
leading cause of morbidity and mortality, accounting 
for more than 40% of all outpatient visits, and for 19% 
of deaths among under five years children [2]. The high 
burden of malaria in D.R. Congo can be explained by 
the fact that nearly the entire population (97%) lives in 
high-transmission zones where the most common vector 
encountered is Anopheles gambiae, and Plasmodium fal-
ciparum is the most common species responsible for the 
majority of severe cases [2, 3].
An important component of malaria control and elimi-
nation is appropriate case management, which is based 
on early and accurate diagnosis. Accurate diagnosis facil-
itates appropriate and prompt treatment and minimizes 
the risk of developing drug resistance [1].
The WHO recommends microscopic examination as 
the gold standard for malaria diagnosis. However, in rural 
and semi-urban settings where lack of equipment, rea-
gents, trained and skilled personnel, and electricity can 
prevent this diagnosis method, the use of rapid diagnos-
tic tests (RDTs) offers an alternative for quick and accu-
rate diagnosis [4, 5].
RDTs have become a primary and critical tool for 
malaria diagnosis in the D.R. Congo as well as in Malaria 
endemic countries. They accounted for nearly 75% of 
diagnostic testing among suspected cases in Africa in 
2017 [1]. Current RDT kits are designed to detect either 
P. falciparum alone or in combination with other spe-
cies of human malaria parasites. Three main antigens are 
detected by malaria RDTs, namely P. falciparum histidine 
rich protein 2 (PfHRP2), parasite lactate dehydrogenase 
(pLDH), and parasite aldolase (pAldo) [6, 7].
PfHRP2, a P. falciparum specific antigen, has the advan-
tage of being highly abundant and heat-stable. PfHRP2-
based RDTs can lead to false-positive results in the case 
of persistent circulating HRP2 antigen as a result of anti-
malarial treatment, and false-negative results in individu-
als whose levels of parasitaemia is under the detection 
threshold of 200 parasites/µl [6, 7].
In the last decade, however, some studies have reported 
false-negative results among individuals infected with 
P. falciparum parasites presenting a deletion of the P. 
falciparum histidine-rich protein 2 (pfhrp2) gene. The 
majority of these studies have also identified co-existing 
deletions of the P. falciparum histidine-rich protein 3 
(pfhrp3) gene, which produces an antigen that shows 
some cross-reactivity with HRP2 [4, 5, 8–30].
While the WHO recommends not initiating antima-
larial treatment without biological evidence,  selection 
of P. falciparum isolates with pfhrp2 gene deletions  may 
occur when only RDT positive  patients  are treated. The 
non-treated  patients infected by parasites harbouring 
pfhrp2 gene deletions will facilitate the spread of phrp2 
deleted strains, jeopardizing progress towards disease 
control and elimination in low setting countries.
To date, only one study has investigated pfhrp2-deleted 
mutant parasites in D.R. Congo, reporting a country-
wide prevalence of 6.4% among children under-five 
years and providing spatial distribution and population 
genetics of these deletions [14]. However, this nation-
wide study could not explore clinical differences between 
pfhrp2-deleted and wild type P. falciparum malaria due 
to limited clinical data and study population (the major-
ity being asymptomatic and under-five), nor was it able 
to conclude about the relative virulence of pfhrp2-deleted 
parasites.
In order to address the above limitations, we selected 
Kwilu Province which is classified by the D.R. Congo 
National Malaria Control Program (NMCP) as a prov-
ince at high risk of malaria [3]. Kwilu Province is clas-
sified in the tropical facies where malaria transmission 
occurs predominantly during the long rainy season last-
ing 5 to 8  months, and where the number of infected 
bites per people per year ranges from 60 to 400 [3]. Using 
data from a prospective health facility-based cross-sec-
tional study, we aimed to determine the local prevalence 
of the pfhrp2 gene deletion among malaria symptomatic 
patients, and associated clinical, biological, and sociode-
mographic factors in the Kwilu Province (D.R. Congo). 
The aim of this study is to contribute to a better charac-
terization of the prevalence and consequences of pfhrp2 
use of RDTs targeting PfHRP2 and parasite lactate dehydrogenase (pLDH) antigens could limit the spread of deleted 
isolates.
Keywords: Plasmodium falciparum histidine rich protein 2, Gene deletion, False negative, Rapid diagnostic test, 
Symptomatic patient
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deletions in D.R. Congo by providing relevant regional 
data to improve malaria management and control.
Methods
Study design and setting
We used secondary data from a prospective health facil-
ity-based cross-sectional study conducted on individuals 
of all ages, seeking healthcare from October to Decem-
ber 2018 in 34 randomly selected health facilities of three 
health zones in the Kwilu Province (D.R. Congo), Fig. 1.
The Kwilu Province is one of 26 provinces of D.R. 
Congo with an area of 79 906  km2. It is divided into five 
administrative territories: Bagata (including the city 
of Bandundu), Bulungu (including the city of Kikwit), 
Gungu, Idiofa, and Masimanimba [31].
The two selected cities (Bandundu and Kikwit) include 
three of the 24 health zones of the Kwilu Province [31]. 
They are the two main cities in the province and bear the 
highest burden of malaria. pfhrp2 gene deletions were 
previously reported in this region [14, 32].
Bandundu, the capital city of the Kwilu Province, is 
located 400 km from Kinshasa, the capital of D.R. Congo 
[33]. Bandundu covers an area of 222  km2 with a popula-
tion estimated at 950 683 as of 2015 [33]. It has a tropi-
cal wet and dry climate with two seasons. Heavy rainfalls 
and constant heat characterize the rainy season while 
fewer rainfalls are recorded during the dry season. The 
average annual temperature is 26.9  °C [33]. Bandundu 
City has one semi-urban health zone of the same name 
and 17 health areas, including 11 urban and six rural.
Kikwit is the second-largest city in Kwilu Province, 
located in the south-west of D.R. Congo, at 525 km from 
Kinshasa and 400 km from Bandundu. It is the main eco-
nomic city of the province and a commercial hub that 
provides access to diamond-rich regions of Kasaï Prov-
ince and Angola. Kikwit covers an area of 92  km2 with 
an estimated population of 1 326 068 as of 2016 [34]. 
The city has a tropical wet and dry climate with a long 
rainy season from early September through to the end of 
May and a short dry season from early June to the end of 
August. Kikwit City has two urban health zones: Kikwit-
Nord and Kikwit-Sud.
Ethics, consent, and permissions
The study was approved by the Kwilu Province Divi-
sion of Health (N° ADM/707/01/DPS-KLU/CD/
JPBK/632/2018), the Kinshasa School of Public Health 
Ethical Committee (ESP/CE/015/2019) and the School 
of Tropical Medicine and Global Health Ethical Review 
Committee.
The study was first explained to all participants, then 
written and verbal voluntary informed consent was 
Fig. 1 Collection sites
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obtained from all study participants including guardian/
parents of non-adult participants.
Study population
The study population included individuals of all ages 
seeking health care in health facilities located in the three 
Health Zones of Bandundu (one) and Kikwit (two) cit-
ies. Health facilities included General Reference Hospi-
tals, Reference Health Centres, and Health Centres. The 
smallest selection units were individuals attending these 
health facilities with symptoms suggestive of malaria. The 
study included all individuals seeking care in the selected 
health facilities with symptoms suggestive of malaria 
such as fever, headaches, malaise; during the study period 
for whom a laboratory test (PfHRP2-RDT and/or micro-
scopic examination) was performed. Individuals who 
failed to meet the inclusion criteria or did not consent to 
participate in the study were excluded.
Sample size calculation
The minimum number of subjects required to enrol in 
this study was calculated based on a previously reported 
proportion of pfhrp2 gene deletion in the Kwilu Province 
(3%) and recommendations from WHO for studies on 
pfhrp2/3 deletion among symptomatic patients [14, 35]. 
According to the WHO protocol for estimating pfhrp2/3 
deletion prevalence, for an expected prevalence of 3.2%, 
at least 370 individuals with P. falciparum infection are 
required per sampling domain [35]. In this study, the 
sampling domain was the Kwilu province, which included 
34 health facilities. The study enrolled a total of 684 
patients meeting the inclusion criteria of which 491 were 
positive for P. falciparum using PCR.
Recruitment method
The primary study applied a two-stage random sampling 
to select health centres. At stage one, 27 health centres 
were randomly selected among the 62 health centres 
in the targeted areas. For neighbouring health centres, 
one health centre was randomly selected out of two. In 
order to increase the chance of catching individuals not 
respecting the referral system by directly seeking care 
in high-level health facilities, four reference health cen-
tres and three general reference hospitals from the three 
health zones were included, bringing the total number of 
selected health facilities to 34 (27 in Kikwit and seven in 
Bandundu).
At stage two, individuals attending the selected health 
facilities with symptoms indicative of malaria were 
recruited. The lead investigator weighed the number of 
individuals to recruit per health centre to the average rate 
of service utilization provided by the National Health 
Information System.
Variables
This study used four groups of variables: sociodemo-
graphic, malaria prevention, clinical and biological 
variables. Plasmodium falciparum HRP2 gene deletion 
(pfhrp2) was the main outcome variable. Explanatory 
variables were age, sex, health zones, household size, 
existence of mosquito breeding sites, LLIN (Long Lasting 
Insecticidal Net) ownership, use of LLIN, malaria drug 
intake, malaria clinical features, parasite density, and 
microscopy result.
Data collection method
Potential participants were introduced to the study by a 
research assistant. After securing consent/assent from 
the subjects or their guardians, socio-demographic, 
malaria prevention and treatment practices, and clini-
cal variables were collected using a pre-tested structured 
questionnaire. Patients’ medical records were used to 
collect data from the physician’s or health officer’s clinical 
examination.
Heel or finger-prick blood was collected from each 
individual. Samples for microscopy were prepared using 
two drops of blood. Then 50 µl of blood were applied on 
PfHRP2-RDT, and a few drops were spotted onto What-
man filter paper to prepare dried blood spots (DBS).
The membranes of spent PfHRP2-RDT cassettes and 
the DBSs were individually stored in plastic bags, sealed 
with a desiccant at room temperature before being 
shipped to the Institute of Tropical Medicine in Nagasaki 
(NEKKEN) where they were refrigerated at 4 °C.
Malaria RDT screening
The CareStart™ Malaria Pf (HRP2) Ag RDT (Access Bio, 
Inc., Somerset, New Jersey, USA) was used for the quali-
tative detection of malaria histidine-rich protein 2 in the 
whole blood according to the manufacturer’s instructions 
[ACCESSBIO, 2018, Somerset, New Jersey, USA]).
The test membrane strip is pre-coated with a P. falcipa-
rum HRP2 specific monoclonal antibody as a single line 
across the test strip. The reported panel detection score is 
91.0% at 200 parasites/µl with a false positive rate of 0.9% 
[36, 37]
Microscopic diagnosis of malaria
A team of four medical technologists read the slides in 
the laboratories of health facilities where samples were 
collected. When a health facility did not have the neces-
sary equipment to perform the examination, slides were 
read at the nearest laboratory possessing adequate equip-
ment. For quality assurance, one expert microscopist 
randomly selected positive and negative slides to cross-
check results. In the case results were not concordant, 
another reading was performed. About five percent of 
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slides went through another quality control in the vec-
tor control laboratory of the Kinshasa School of Public 
Health.
Thick and thin smears were made on the same slide. 
The part of the slide containing the thin smear was 
fixed with methanol and dried. Then the whole slide 
was stained with 10% Giemsa’s solution for ten minutes 
and finally washed off with distilled water and air-dried. 
Stained smears were examined under a microscope 
for malaria parasite identification. For positive slides, 
malaria parasites were counted against 200 white blood 
cells (WBC), and parasite density was calculated based 
on a total of 8000 WBC/µl using the following for-
mula: (Number of Parasites counted × 8000)/Number of 
counted WBC.
Parasite density calculation was immediately per-
formed when 100 parasites were counted against 200 
WBC. However, in the case that fewer than 100 parasites 
were counted against 200 WBC, the count continued 
until 500 WBC.
Extraction of parasite DNA
Genomic DNA was extracted from membranes of spent 
PfHRP2-RDT cassettes and DBS using the QIAGEN 
QIAmp®DNA extraction kit (company, city, country) 
according to the manufacturer’s instructions. We also 
adapted a previously described method to recover DNA 
from 197 spent RDTs membranes from Bandundu Health 
Zone [38].
Detection of P. falciparum infection & pfhrp2 gene deletion
To confirm P. falciparum infection, we designed specific 
primers targeting a 226 base pair region of the P. falcipa-
rum lactate dehydrogenase (pfldh) gene and performed a 
real-time PCR assay (Table  1). This assay was also used 
to ensure there was sufficient parasite DNA quantity in 
the samples to discriminate P. falciparum negative sam-
ples from samples with pfhrp2 gene deletion, as shown in 
Fig. 2.
Samples were duplicated and loaded in 96-wells plates 
along with serially diluted positive controls (gDNA from 
in  vitro cultured P. falciparum strain 3D7) (1  ng/µl, 
0.1 ng/µl, 0.01 ng/µl, 0.001 ng/µl), as well as negative con-
trols containing DNA from blood spots prepared from 
known malaria negative individuals. We repeated the 
assay for all discordant duplicates and counted three con-
sistent results as the final result.
For detection of the pfhrp2 gene, we performed a 
nested PCR assay using primers targeting a 228 base pair 
fragment spanning exon 1, the intron, and a portion of 
exon 2 of pfhrp2 as previously described (Table 1) [9]. We 
used a lower elongation temperature (68 °C) to improve 
PCR sensitivity, pfhrp2 being AT-rich, and increased the 
number of cycles to 40. We used genomic DNA from 
Table 1 Primer sequences and PCR conditions for pfhrp2 and pfldh genes amplification
LOD Lower limit of detection, qPCR Quantitative or real-time PCR
Targeted gene Primer sequence (5′ → 3′) Reaction component Cycling condition LOD
(ng/µl)
pfhrp2 Exon 1–2, 
PF3D7_0831800
Outer
For: GGT TTC CTT CTC AAA AAA TAAAG 
Rev: TCT ACA TGT GCT TGA GTT TCG 
One Taq 2 × Master 
Mix with standard 
buffer: 12.5 µl
10 µmol/L forward 
primer: 1 µl
10 µmol/L reverse 
primer: 1 µl
Nuclease free water: 
7.5 µl
DNA template: 3 µl 
(gDNA or 5 × diluted 
outer PCR product
25 µl reaction volume
95 °C/5 min;





For: GTA TTA TCC GCT GCC GTT TTT GCC 
Rev: CTA CAC AAG TTA TTA TTA AAT GCG GAA 
95 °C/5 min;
40 cycles of 95 °C/30 s, 62 °C/30 s, 68 °C/30 s
68 °C/5 min
4 °C–∞
pfldh (qPCR) For: ACG ATT TGG CTG GAG CAG 
Rev: GGA ACA CCT GAA TGT TGA TG
PowerUp™ SYBR ™ 
Green Master Mix 
(2 ×): 12.5 µl
10 µmol/L forward 
primer: 0.5 µl
10 µmol/L reverse 
primer: 0.5 µl
Nuclease free water: 
6.5 µl
DNA template: 2–4 µl




45 cycles of 95 °C/15 s, 62 °C/1 min, 95 °C/30 s, 
60 °C/15 s
10–4
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Dd2 (pfhrp2 negative) and 3D7 (pfhrp2 positive) as con-
trols for all assays.
We repeated the nested PCR for all negative results. In 
the case of discordant results, we performed the amplifi-
cation a third time and counted two consistent results as 
the final result.
Reaction components for both real-time and nested 
PCR are summarized in Table 1.
PCR product resolution by agarose gel electrophoresis
PCR amplicons were separated by electrophoresis on a 
2% agarose gel stained with Gel Red® Nucleic Acid Stain 
10 000 × in water. A total of 12  µl of PCR amplicons 
(6  µl) and loading dye (6  µl) were loaded onto the gel, 
which was run for 35 min at 100 V and observed under 
UV light. A 500 µg/ml Gene Ruler 100 bp DNA Ladder 
(BioLabs®inc, Ipswich, USA) was loaded onto the same 
gel to determine the sizes of the resolved fragments.
Statistical analyses
Data were entered and analyzed using STATA15 (Stata-
Corp LLC, Lakeway, Texas, USA). Tables have been used 
to describe categorical variables. Continuous variables 
have been summarized using median and interquartile 
ranges. Proportions have been used to summarize cat-
egorical variables.
Fischer’s exact test (for categorical variables) and the 
Kruskal–Wallis test (for non-normally distributed con-
tinuous variables) were applied to look for associations 
between potential explanatory variables and the main 
outcome (pfhrp2 gene deletion). We computed the 95% 
Confidence Interval (95% CI) for the prevalence of pfhrp2 




Of the 684 symptomatic patients who participated in the 
study; 391 (57.7%) were female, and 287 (42.3%) were 
male. Kikwit-Nord Health Zone accounted for the major-
ity of patients 362 (52.9%) while Bandundu and Kikwit-
Sud Health Zones accounted for 197 (28.8%) and 125 
(18.3%) patients, respectively.
The median age was nine years, with an interquartile 
range from 3 to 26  years old. Children under five years 
old represented 36% of enrolled patients. The median 
size of household was six, with an interquartile range 
from five to six. Table 2 summarizes socio-demographic 
characteristics.
Household environment, malaria prevention, 
and treatment practices
The majority (87.7%) of patients/patients’ guardian 
reported the presence of mosquito breeding sites within 
the compound where the household was located. Two-
thirds of household (64.2%) owned a mosquito bed-
net, while 49.7% of patients spent the night before the 
interview under a mosquito bed net. One-third (220) 
Fig. 2 pfhrp2 gene deletion testing pipeline
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of patients reported prior malaria drug intake. Quinine 
(13%), sulfadoxine-pyrimethamine (6.1%), artemether-
lumefantrine (4.8%), artesunate (2.0%), arteether (1.9%), 
artemether (1.8%) were the common drugs taken as illus-
trated in Table 2.
Clinical and biological features of symptomatic patients
At admission, the body temperature of patients ranged 
from 37 °C to 38 °C (median temperature of 37.5 °C). The 
common findings of the clinical examination were: A 
history of fever the last 72 h (81.6%), headaches (41.8%), 
vomiting (31.4%), rigor (22.8%), fatigue (22.1%) and 
abdominal pain (20.2%). Among the 235 patients with 
a microscopy positive result, malaria parasite density 
ranged from 64 parasites /µl to 7200 parasites /µl with 
a median parasite density of 880 parasites/µl. Table  3 
summarizes the distribution of clinical and biological 
features.
Comparison of RDT, PCR and microscopy
Among patients with a negative PfHRP2-RDT result, 
63.9% were ‘false negatives’ compared to PCR. The sensi-
tivity and specificity of RDTs with reference to PCR were 
71.3% (325/456) and 42.4% (74/173), respectively. Using 
microscopy as the gold standard, the proportion of false-
negative RDT result dropped to 26.3%. The microscopy-
determined sensitivity and specificity of RDTs were 74.3% 
(156/210) and 36.0% (151/419), respectively (Table 4).
Proportion of pfhrp2 gene deletion in false‑negative 
PfHRP2‑RDT
Using PCR as the gold standard, there were 131 false-
negative PfHRP2-RDT results of which only 9.9% were 
due to pfhrp2 gene deletion, with a 95% CI ranging from 
5.4% to 16.4%. The mean parasitaemia of the 131 RDT 
false-negative infections was 2447 parasites per µl. The 
theoretical limit of detection of PfHRP2-RDT is 200 
parasites per ul of blood. Of 155 samples with parasite 
densities of over 200 parasites per ul as determined by 
microscopy, 30 were negative by RDT (19%). Of these, 
only one harboured a deletion at the PfHRP2 locus.
Table 2 Socio-demographic characteristics, household 
environment and malaria prevention and treatment practices
For the variable sex, less than 1% information is missing (six entries). For the 
variable age, less than 1% information is missing (four entries)
Malaria drug taken includes only individuals who reported malaria drug intake 
at least one week before the survey
IQR Inter quartile range, LLIN Long lasting insecticidal net
Characteristic n % Median IQR
Sex (n = 678)
 Female 391 57.7
 Male 287 42.3
Health Zone (n = 684)
 Bandundu 197 28.8
 Kikwit-Nord 362 52.9
 Kikwit-Sud 125 18.3
Age in years (n = 680) 9 3–26
 < 5 245 36.0
 > 5 435 64.0
Household Size (n = 684) 6 5–8
Household environment (n = 684)
 Mosquito breeding sites 600 87.7
 LLIN ownership 439 64.2
 LLIN utilisation 340 49.7
Malaria prevention and treatment practices
 Prior drug intake (n = 684) 220 32.2
 Malaria drug taken (n = 220)
 Quinine 89 13.0
 Sulfadoxine–pyrimethamine 42 6.1
 Artemether–lumefantrine 33 4.8
 Artesunate 14 2.0
 Arteether 13 1.9
 Artemether 12 1.8
 Arteether-artemotil 10 1.5
 Amodiaquine 4 0.6
 Artesunate-sulfadoxine-pyrimethamine 2 0.3
 Plant extract 1 0.1
Table 3 Clinical and biological features of symptomatic patients
IQR Inter quartile rRange, LLIN Long lasting insecticidal net
Characteristic n % Median IQR
Clinical features (n = 684)
 History of fever 558 81.6
 Headache 286 41.8
 Vomiting 215 31.4
 Rigor 156 22.8
 Fatigue 151 22.1
 Abdominal pain 138 20.2
 Joint Pain 58 8.5
 Anorexia 42 6.1
 Neckache 34 5.0
 Diarrhoea 32 4.7
 Pallor 13 1.9
 Convulsions 12 1.8
 Splenomegaly 5 0.7
 Impaired consciousness 3 0.4
 Temperature at admission (°C) 37.5 37–38
Biological features (n = 235)
 Parasite density (parasites /µl) 880 64–7200
P arasite density accounts for only microscopy positive samples
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Prevalence of pfhrp2 gene deletion among all 
symptomatic PfPCR confirmed cases
The overall prevalence of pfhrp2 gene deletion among 
PfPCR confirmed symptomatic cases was 9.2%. The 
highest prevalence was found in Bandundu Health Zone 
(15.7%), followed by Kikwit-Sud Heath Zone (9.6%) and 
Kikwit-Nord Health (6.2%). Table  5 shows the distribu-
tion of pfhrp2 gene deletion among PCR confirmed cases 
across Heath Zones.
Socio‑demographic, malaria prevention, biological 
features, and pfhrp2 gene deletion
As shown in Table 6, there was no statistically significant 
difference in pfhrp2 gene deletion status between males 
and females (8.5% vs 9.8%). Conversely, there was a sta-
tistically significant difference in pfhrp2 gene deletions 
status in Bandundu health zone compared to Kikwit-
Nord and Kikwit-Sud health zones (P = 0.012). There 
was a trend towards pfhrp2 gene deletion in older com-
pared to younger patients, but this was not statistically 
significant (P = 0.079). However, when analyzing age as a 
continuous variable, the median age among pfhrp2 gene 
deleted patients was higher than the median age among 
pfhrp2 gene non-deleted patients (18  years vs 7  years). 
The Kruskal Wallis test showed strong evidence suggest-
ing that the distributions of age differed by pfhrp2 gene 
deletion status (P = 0.019). Similarly, there was a trend 
towards pfhrp2 gene deletion among negative micros-
copy results, but weak evidence supported this finding 
(P = 0.079).
Clinical features and pfhrp2 gene deletion
We found more malaria signs and symptoms among 
patients infected with parasites not harbouring pfhrp2 
gene deletion. However, the difference was not statisti-
cally significant (Table 6).
Discussion
More females participated in this study than males (57% 
vs 42.3%). This finding is in keeping with results from 
the D.R. Congo 2013–2014 Demographic and Health 
Survey(DHS) which reported a sex ratio slightly in favour 
of females [39].
Surprisingly, children under-five represented 36% 
of participants. This is in contrast with what might be 
expected since under-five children are known to be at 
higher risk of contracting malaria. Despite the burden 
of malaria in Kwilu Province, there is a seasonal trend 
in transmission, and immunity is acquired later in life, 
around 10 years [3]. Late acquisition of immunity can 
explain the higher proportion of participants aged more 
than five years, seeking treatment for symptoms sug-
gestive of malaria and thus enrolled in this study. The 
median household size of six is similar to findings from 
the 2013–2014 DHS which reported of median size of 5.7 
[39].
There were mosquito breeding sites near households of 
the majority of participants (87.7%). The survey was con-
ducted during the rainy season, which is characterized 
by the formation of breeding sites, especially in rural and 
semi-urban areas with limited public facilities.
Table 4 Comparison of HRP2-RDT, PCR, and microscopy
HRP2-RDT Histidin Rich Protein 2 based rapid diagnostic test, PCR Polymerase chain reaction
HRP2‑RDT (n = 629) PCR Microscopy
Negative Positive Negative Positive
n % n % n % n %
Negative 74 36.1 131 63.9 151 73.7 54 26.3
Positive 99 23.3 325 76.7 268 63.2 156 36.8
Table 5 Frequency of pfhrp2 gene deletion among all symptomatic PfPCR confirmed cases
PCR Polymerase chain reaction, CI Confidential interval
Health Zones Subjects Plasmodium falciparum infection pfhrp2 gene deletion
n Prevalence (95% CI) n Prevalence (95% CI)
Overall 684 491 71.8 (68.2–75.1) 45 9.2 (6.7–12.1)
Bandundu 197 121 61.4 (54.2–68.2) 19 15.7 (9.7–23.4)
Kikwit-Nord 362 276 76.2 (71.5–80.5) 17 6.2 (3.6–9.7)
Kikwit-Sud 125 94 75.2 (66.7–82.5) 9 9.6 (4.5–17.4)
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The use of mosquito bednets was the primary means 
of bite-prevention. Two-thirds of households (64.2%) 
owned a bednet, and only 49.7% of participants spent 
the night before the interview under a mosquito bednet. 
These results are lower than the previous report from 
the DHS in Kwilu Province. In 2014, 87% of households 
surveyed in the Kwilu province possessed a bednet, and 
69.4% of participants slept under a bednet the night 
before the interview [39]. Back then, an extensive mos-
quito bednet distribution campaign was implemented 
with a higher rate of implementation, especially in Kwilu. 
However, Mwandagalirwa et  al. recently reported con-
sistent data (72% ownership vs 45% use) in health zones 
of Kinshasa province, neighbouring Kwilu province [40]. 
Table 6 Socio-demographic, malaria prevention, biological features and pfhrp2 gene deletion
Kruskal Wallis test (*) has been used to compare distributions for continuous variables (parasite density, age, and household size), Fischer exact test has been used for 
categorical variables
Pfhrp2: Plasmodium falciparum Histidin Rich Protein 2 gene, IQR Inter quartile range, LLIN Long lasting insecticidal net
Characteristic pfhrp2 gene deleted pfhrp2 gene non‑deleted P‑value
n % Median IQR n % Median IQR
Sex (n = 487)
 Female 27 9.8 248 90.2 0.640
 Male 18 8.5 194 91.5
Health Zone (n = 491)
 Bandundu 19 15.7 102 84.3 0.012
 Kikwit-Nord 17 6.2 259 93.8
 Kikwit-Sud 9 9.6 85 90.4
Age in years (n = 488) 18 4.9–30 7 2.9–19 0.019*
 < 5 12 6.3 179 93.7 0.079
 > 5 33 11.1 264 88.9
Household size (n = 491) 7 6–8 6 5–8 0.388*
Mosquito breeding sites (n = 491)
 Absent 8 14.0 49 86.0 0.217
 Present 37 8.5 397 91.5
LLIN ownership (n = 491)
 No 16 9.0 161 91.0  > 0.999
 Yes 29 9.2 285 90.8
LLIN utilization (n = 491) 24 9.5 228 90.5 0.876
 No 21 8.8 218 91.2
 Yes
Prior drug intake (n = 491)
 No 29 9.0 295 91.0 0.869
 Yes 16 9.6 151 90.4
Microscopy (n = 491)
 Negative 33 11.1 265 88.9 0.079
 Positive 12 6.2 181 93.8
Parasite density (n = 491) 4680 264–14 800 1200 112–8080 0.3771*
Clinical features (n = 491)
 Temperature at admission (°C) 37.5 36.4–38.6 37.8 37–38 0.345*
 History of fever 34 8.4 371 91.6 0.217
 Headache 19 9.4 183 90.6 0.875
 Vomiting 11 6.6 156 93.4 0.187
 Rigor 5 4.4 108 95.6 0.061
 Fatigue 9 8.3 99 91.7 0.851
 Abdominal pain 5 4.8 100 95.2 0.087
 Joint pain 3 7.7 36 92.3 1.000
 Anorexia 3 9.4 29 90.6 1.000
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A low coverage during bednet distribution campaigns 
can explain the lower proportion of household possessing 
bed net. Also, bednet usage is known to be higher among 
under-five children and falls progressively to as low as 
34% by the early twenties [40]. Subsequently, the majority 
of participants (64%) being over five years may account 
for the majority of participants not using bednets.
Among participants who reported prior malaria drug 
intake, 13% took quinine at least one week before the 
survey. This finding highlights the poor compliance with 
the WHO guidelines for the treatment of malaria in the 
study areas as well as challenges associated with the use 
of injectable artesunate in areas where quinine is cheaper, 
easy to use and available.
As might be expected, 81.6% of participants reported 
a history of fever. In many cases, fever is suggestive of 
malaria but is also reported in several febrile illnesses 
prevailing in tropical areas. Without a reliable diag-
nostic tool, a syndromic approach often leads to over-
treatment, especially among people living in low to 
moderate malaria transmission areas [41]. A recent anal-
ysis of household survey data from 24 Sub-Saharan Africa 
countries between 2006 and 2014 showed that 35.7% of 
all fevers reported by participants were accompanied by 
malaria infection evidence, but only 10% of these fevers 
were attributable to malaria [42]. Non-malarial febrile ill-
nesses (NFMI) can coincide with malaria infection, and 
may lead to over-diagnosis of malaria and underestima-
tion of the burden of associated NFMI [42].
Only 9.9% of false-negative PfHRP2-RDT results 
involved parasites with pfhrp2 gene deletions. A similar 
result (10.6%) has been reported in Nigeria, [24]. Con-
versely, Wurtz et al. (2013), in Senegal reported a lower 
proportion (2.4%) while Amoah et al. (2016), in Ghana 
reported a higher proportions of 23% [4, 5, 17].
This weak proportion shows that pfhrp2 gene dele-
tion is not a major cause of false-negative PfHRP2-RDT 
results. Several reasons may explain a false-negative 
PfHRP2-RDT result such as poor quality of the test, inap-
propriate manipulation and interpretation, low parasite 
density, excess of circulating parasite antigens creating 
a prozone-like effect, and genetic polymorphisms in the 
target antigen [6, 23, 43, 44].
Even though the proportion of PfHRP2-RDT false-neg-
ative results due to pfhrp2 gene deletion has surpassed 
the 5% threshold set by the WHO, requiring a subna-
tional change in malaria RDTs, the required number of 
P. falciparum isolates (37) to include per health facility in 
the sampling domain was not reached. Therefore, further 
investigations are needed to provide enough evidence for 
policy change.
The overall prevalence of P. falciparum isolates with 
pfhrp2 gene deletion was 9.2%. This prevalence is higher 
than the previously reported national prevalence of 6.4% 
and the local prevalence of 3% [14]. The present study 
exclusively enrolled subjects with symptoms sugges-
tive of malaria and thus more likely to be infected while 
the previous one included more asymptomatic subjects. 
Secondly, Kwilu Province is located in a low to moder-
ate transmission area where immunity is acquired later in 
life. This condition of reduced host immunity is favour-
able to infection by parasites harbouring pfhrp2 gene 
deletion, which can survive and spread [18]. Thirdly, the 
prevalence of parasites harbouring pfhrp2 gene deletion 
has been shown to be higher in low to moderate trans-
mission area in the beginning of the rainy season, which 
is the case for the present study [45].
A similar prevalence has been reported in Eritrea 
(9.7%) and Kenya (9%) [13, 46]. However, lower preva-
lence has been reported in Senegal (2.4%), Mozambique 
(1,4%) and higher prevalence in Nigeria (17%), Ghana 
(36%) and Zambia (37.5%) [4, 15–17, 24, 25]. The differ-
ence in study design and methodology used for deletion 
confirmation (nested PCR vs qPCR of a single-copy gene) 
could explain the discrepancy. Publications using nested 
PCR for confirmation of deletion tend to overestimate 
the prevalence while amplification of a single-copy gene 
by real-time PCR is recommended for appropriate dele-
tion call [47, 48].
The first protocol concerning phrp2/3 deletions was 
released in 2014 [49]. Subsequently, the WHO released 
a second protocol in 2018 for estimating phrp2/3 dele-
tions among symptomatic patients [35]. Finally, Parr et al. 
revised the existing protocols and released a streamlined 
protocol taking into account challenges faced by previous 
authors [48].
There was a statistically significant difference in 
pfhrp2 gene deletion prevalence in Bandundu health 
zone compared to Kikwit-Nord and Kikwit-Sud health 
zones (P = 0.012). Variations in pfhrp2 gene deletion sta-
tus within regions and countries have been previously 
reported and depend on several factors including level 
of transmission and magnitude of PfHRP2-RDT use [10, 
12, 20, 50]. Further analysis of population genetics may 
clarify this finding.
There was a trend towards pfhrp2 gene deletion in 
older compared to younger (under-five) patients, but 
this was not statistically significant (P = 0.079). How-
ever, when analyzing age as a continuous variable, the 
Kruskal Wallis test showed strong evidence suggesting 
that the distributions of age differed by pfhrp2 gene dele-
tion status (P = 0.019). This may suggest that the risk of 
being infected with parasites harboring pfhrp2 deletion 
increases with age while traditionally under-5 years old 
are at high risk of contracting malaria compared to the 
older group.
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Similarly, there was a trend towards pfhrp2 gene dele-
tion among negative microscopy results, but weak evi-
dence supported this finding (P = 0.079). Microscopic 
examination is based on morphological aspects of the 
parasite and might not be influenced by genetic traits 
such as gene deletions. Even considering that PfHRP2 is 
known to be involved in the formation of hemozoin, this 
is not the only morphological feature allowing parasite 
detection by microscopic examination.
We found more malaria signs and symptoms among 
patients infected with parasites not harbouring pfhrp2 
gene deletions. However, the difference was not statisti-
cally significant. This study could only identify 45 P. fal-
ciparum isolates with pfhrp2 gene deletions, and a larger 
sample size may be required to detect differences and 
provide evidence of association.
This study is the first to provide the local prevalence of 
P. falciparum isolates with pfhrp2/3 gene deletion among 
symptomatic patients in this region. The availability of 
clinical, biological, and sociodemographic data allowed 
exploration of differences between infection by pfhrp2-
deleted and wild-type P. falciparum parasites. However, 
the limited sample size precluded identification of pre-
dictors of pfhrp2 gene deletion and did not allow us to 
make solid conclusions regarding differences in pathol-
ogy between pfhrp2 deleted and wild-type parasites.
The selection of study sites based on known burden of 
malaria and sociodemographic characteristics may have 
introduced a selection bias making the sample not rep-
resentative of the whole province within which the level 
of transmission varies. A health facility-based design 
is undoubtedly the best choice to recruit symptomatic 
patients, but the low service utilization rate and insuffi-
cient public subsidies allocated to malaria management 
may have prevented some subjects with the character-
istic of interest to attend health facilities and thus to be 
enrolled in the study.
The D.R. Congo National Malaria Control Program 
has adopted a five year (2016–2020) strategic plan with 
goals including the diagnosis of at least 80% of fever cases 
and the treatment of all positive diagnosed cases with 
ACT. Increased service utilization, the significant use of 
PfHRP2 based RDTs as primary diagnostic tools and co-
infections with non-malaria febrile illnesses could lead 
to the initiation of a selective treatment favoring pfhrp2 
deleted parasites. There is a need, therefore, to establish 
a surveillance system for pfhrp2 deleted mutants as a part 
of malaria control programs. Such a surveillance system 
should be strengthened with reliable diagnostic tools 
such as molecular point of care testing to ensure efficient 
and evidence-based allocation of resources to disease 
control programs.
In routine practice, clinicians should investigate other 
febrile illnesses despite a positive RDT result to minimize 
failure in disease management.
Conclusions
We found a local prevalence of 9.2% of P. falciparum iso-
lates with a pfhrp2 gene deletion among symptomatic 
patients. These isolates explained only 9.9% of PfHRP2-
RDT false-negative results, suggesting that factors other 
than pfhrp2 gene deletion are of significant importance 
in the false-negativity rates of PfHRP2-based RDTs. Even 
though the proportion of false-negative PfHRP2-RDT 
results due to the pfhrp2 deletion has surpassed the 5% 
threshold set by the WHO for a subnational change in 
malaria RDTs, further regional investigations with appro-
priate sampling are needed to provide enough evidence 
for policy change. Meanwhile, the use of RDTs target-
ing PfHRP2 and pLDH antigens could limit the spread of 
deleted isolates.
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